[{"orgOrder":0,"company":"Eisai","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai Enters Industry-Academia-Government Joint Research Agreement","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Eisai"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$1,890.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sosei Announces Second Novel Drug Candidate from Its Multi-Target Drug Discovery Collaboration with Pfizer has Started Clinical Trials","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sosei Heptares"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
This candidate is the eighth GPCR-targeted drug candidate to enter clinical trials originating from Sosei Heptares’ StaR® technology and structure-based drug design (SBDD) platform.
In this project, Eisai aims at creating a Japan-originated therapeutic drug for systemic lupus erythematosus (SLE) through industry-academia-government collaboration, using its in-house discovered new oral Toll-Like Receptor (TLR) 7/8 inhibitor E6742.